Synspira begins Phase Ia of SNSP113 for CF

Synspira LLC. (Cambridge, Mass.) began part A of a Phase I trial to evaluate single ascending doses of SNSP113 to treat pulmonary complications of cystic fibrosis (CF). Part A is enrolling healthy volunteers. Part B, slated to begin next year, will evaluate SNSP113 in patients with stable CF. The double-blind, placebo-controlled trial will enroll 41 subjects total. The primary endpoints are safety and change from baseline in spirometry and pulse oximetry. Secondary endpoints will assess pharmacokinetics.

SNSP113 is an inhaled glycopolymer-based therapeutic...